Zydus Life shares rise after drug maker gets US regulator's nod for bronchospasm treatment injection

Zydus Lifesciences shares rose on Monday after the drug maker received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Isoproterenol Hydrochloride injection, used in the treatment of bronchospasm that occurs during anaesthesia. Zydus Life shares rose as much as 1.1 per cent to Rs 509.3 apiece on BSE after the news.

The drug, which also helps in the treatment of distributive shock and shock owing to decreased cardiac output in patients, will be manufactured at the company's injectable manufacturing facility at Jarod near Vadodara, according to a company statement.

The latest approval included, Zydus has received a total of 362 approvals, and so far filed more than 440 ANDAs since starting the filing process in the financial year 2003-04.

US FDA approval for Azithromycin Tablets USP (500 mg)

On April 10, Zydus announced that it had received final approval from the US drug regulator to manufacture Azithromycin Tablets USP (500 mg).

Azithromycin is used to treat certain bacterial infections such as bronchitis, pneumonia, STD, infections of the ears, lungs, sinuses, skin, throat and reproductive organs. Zydus will manufacture this drug at its formulation manufacturing facility in Moraiya, Ahmedabad.

Zydus shares

Zydus' shares have gained more than six per cent in value in the past one month, a period in which the Nifty50 headline index has risen three per cent.

ALSO READ: Share Market Today LIVE: Nifty 50 cracks below 17,600, Sensex drops 800 pts dragged by Infosys, HDFC Bank